Our Strategy

We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.

Typical Investments

Investment size$15-$30m in total per company
OwnershipMajority or minority
GeographyPrimarily US and Europe
Holding period3-8 years
SectorsBiotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation

BROAD STRATEGIC APPROACH

Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.

Discover the Strategies

Covering programmes and companies at many different stages of development, our diverse strategies provide us with unusually broad insights into the key factors for success in biotechnology.

"Abingworth was the original lead investor in SFJ and has since made 5 additional investments in SFJ related companies. Working together to maximize the full potential growth and sustainability of SFJ, we have formed a true partnership with the Abingworth team."

Robert DeBenedetto, President and CEO of SFJ Pharmaceuticals

"I was impressed by Abingworth’s thoughtful, candid and rigorous diligence process, and their interest in building a relationship with management before they became investors. That approach created mutual understanding and trust, and laid the foundation for a highly productive partnership."

Timothy Noyes, President and CEO of Proteon Therapeutics

"I have found Abingworth to be extremely supportive in positioning Paratek for success. In addition to providing finance and executive leadership, their deep knowledge of the sector and extensive network have proven to be invaluable in creating value for the company today and in the future."

Evan Loh, President of Paratek Pharmaceuticals

"The business acumen and scientific insight provided by multiple members of the Abingworth team is invaluable to a young company like IFM. We are fortunate to be working with them as we grow and develop the company."

Gary Glick, CEO of IFM Therapeutics

"Abingworth is an excellent investor for GammaDelta Therapeutics. Using strong scientific expertise and astute business sense they drove the seed investment with King’s College and the Crick institute and then our highly productive collaboration with Takeda. High quality science and ethical behaviour form the foundation of day-by-day activities at Abingworth and it is extremely reassuring to have such partners."

Paolo Paoletti, CEO of GammaDelta Therapeutics